Immunome announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. “Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients,” said Bob Lechleider, M.D., Chief Medical Officer at Immunome. “The dosing of our first patient with IM-1021 advances that mission, as we work to establish safety and explore efficacy of IM-1021 in patients with high unmet need in B-cell lymphomas and solid tumors.” IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021. The study is expected to include participants with advanced B-cell lymphomas and advanced solid tumors. https://lnkd.in/ekrRhNNb
关于我们
Immunome is a clinical-stage targeted oncology company committed to developing first-in class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, IM-1021, a ROR1 ADC with an active IND, and IM-3050, a FAP-targeted radioligand, which is the subject of an IND expected to be submitted in the first quarter of 2025. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
- 网站
-
https://www.immunome.com/
Immunome, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Bothell，Washington
- 类型
- 上市公司
- 创立
- 2008
- 领域
- biotechnology、antigen discovery、antibody-drug conjugate therapies和radioligand therapy
地点
-
主要
获取路线
18702 North Creek Pkwy
100
US，Washington，Bothell，98011
Immunome, Inc.员工
-
Erik S. Nelson
Head of Information Technology | Cybersecurity
-
Michael Lefenfeld
-
Shaji Abraham, Ph.D.
Preclinical R&D Scientist | Expert in Molecular & Cellular Biology | Drug Discovery | Oncology | Antibody therapeutics| Omics Research | Project…
-
Robert Morgan
Consultant - Pharmaceutical Development Operations
动态
-
Desmoid tumors can have a dramatic impact on patients. Immunome is evaluating varegacestat (formerly AL102) as an oral, once-daily gamma secretase inhibitor (GSI) therapy for the treatment of Desmoid tumors. Enrollment in RINGSIDE, a Phase 3 registrational trial comparing varegacestat with placebo for the treatment of progressing desmoid tumors, was completed in February 2024, and we expect to report topline data from this trial in the second half of 2025.
?? At the DTRF, we want to “Spread the Word” far and wide that desmoid tumors are NOT benign. The medical community, research publications, and other sources often use differing terms when describing desmoid tumors. Over the years, we’ve heard countless stories that this is confusing to patients as well as clinicians. This confusion can lead to misunderstandings about treatment and minimizes the potentially serious consequences of this rare disease. ?? Desmoid tumors (also known as aggressive fibromatosis, desmoid fibromatosis, and desmoid-type fibromatosis) do not metastasize. They are classified by the World Health Organization (WHO) as “Intermediate (locally aggressive)” soft tissue tumors. They do not fall under “Benign” or “Malignant” classifications. ?? Learn more about desmoid tumors’ classification and much more by visiting our website: https://lnkd.in/e7X-Wb4h ?? In honor of Rare Disease Day on February 28th, you’ll see a variety of awareness and educational content over the next couple of months to help correct this common misconception. To make a significant impact on behalf of the patient community, we invite you to like, share, and spread the word that desmoid tumors are NOT benign. #DesmoidsareNOTbenign #SpreadtheWord #DTRF #DesmoidTumorResearchFoundation #desmoid #desmoidtumor #desmoidawareness #aggressivefibromatosis #Desmoidian #desmoidresearch #FAP #familialadenomatouspolyposis #OrphanDisease #raredisease #sarcoma #sarcomaawareness #oncology #hope
-
-
Immunome will participate in the following investor conferences in March 2025: TD Cowen 45th Annual Health Care Conference Conference Dates: March 3-5, 2025 Presentation Date/Time: March 4, 2025, 1:10 p.m. ET Leerink Partners Global Healthcare Conference 2025 Conference Dates: March 10-12, 2025 Presentation Date/Time: March 10, 2025, 1:40 p.m. ET Live webcast links for both presentations will be available on the events tab of Immunome’s investor website: https://lnkd.in/ghrW_aMh Replay links of the presentations will also be available on the website for 30 days following the live broadcast.
-
Immunome announced today the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, were $172.5 million. All of the shares in the offering were sold by Immunome. Read the press release here: https://lnkd.in/gZhw5X37
-
Immunome announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $150.0 million. Read the full press release here: https://lnkd.in/dXAZkPZ9
-
We are seeking exceptional leaders to join our high-performing team at Immunome, dedicated to accelerating the delivery of targeted therapies to cancer patients. Currently, we have opportunities available in key CMC areas: - Manufacturing & Product Supply - Chemical Process & Analytical Development and Small Molecule QC - Biologics Process Development - Biologics Analytical Development and QC - Regulatory CMC - Executive administrative assistant If you are someone who thinks life is too short, wants to do great things, things that matter, and not satisfied with just showing up at work, I invite you to consider a leadership role within our organization. Take the next step and explore our job postings at Immunome.com in the coming days. Join us in our mission to make a real difference in the lives of cancer patients.